Le Lézard
Classified in: Health, Covid-19 virus
Subjects: MAT, MRR

Medical marijuana market size to grow at a CAGR of 21.86% from 2022 to 2027: The rising number of product launches drives market growth -Technavio


NEW YORK, Aug. 10, 2023 /PRNewswire/ -- The medical marijuana market is estimated to grow by USD 21,248.51 million from 2022 to 2027. The market grows at a CAGR of 21.86% during the forecast period according to Technavio. Discover some insights on market size historic period (2017 to 2021) and Forecast (2023 to 2027) before buying the full report -Request a sample report

Medical marijuana market ? Company Analysis
Company Landscape - The global medical marijuana market is fragmented, with the presence of several global as well as regional companies. A few prominent companies that offer medical marijuana in the market are Aurora Cannabis Inc., Canopy Growth Corp., Cresco Labs LLC, Cronos Group Inc., CV Sciences Inc., Etain LLC, HEXO Corp., Isodiol International Inc., Jazz Pharmaceuticals Plc, Khiron Life Sciences Corp, Maricann Group Inc, Medical Marijuana Inc., MediPharm Labs Inc., Organigram Holdings Inc., Phoena Holdings Inc, Skye Bioscience Inc., Tikun Olam, Tilray Brands Inc., Trevena Inc, and Verano Holdings LLC and others.

What's New? -

Company Offerings -

Medical Marijuana Market - Segmentation Assessment

Segment Overview
Technavio has segmented the market based on type (oil & tinctures and flower), product (chronic pain, nausea, and others),

Geography Overview
By geography, the global medical marijuana market is segmented into North America, APAC, Europe, South America, and the Middle East and Africa. The report provides actionable insights and estimates the contribution of all regions to the growth of the global medical marijuana market.

For insights on global, regional, and country-level parameters with growth opportunities from 2017 to 2027 - Download a Sample Report

Medical Marijuana Market ? Market Dynamics

Key Drivers

The rising number of product launches is a key factor driving market growth. The increase in demand is due to the legalization of cannabis for medical purposes. New product launches help companies increase sales and market share. In May 2021, Curaleaf announced the launch of a new medical cannabis product in Germany. To cater to a wider range of patients, the company also launched high-THC oil products to meet urgent patient demand, expanding its product portfolio throughout the year. Hence, such factors are expected to drive the growth of the market during the forecast period.

Major Trends

The increasing number of awareness campaigns is a major trend in the market. Several companies in the market are launching campaigns to educate consumers about the safe and responsible use of medical cannabis to increase sales. For example, in April 2022, New York City launched its first public health awareness campaign focused on medical cannabis. Governor Kathy Hochul has released a new public service announcement as part of the Cannabis Conversation Campaign. Hence, such trends are expected to boost market growth during the forecast period.

Significant Challenges

Side effects associated with the inappropriate use of medical marijuana are a significant challenge restricting market growth. The active compounds found in medical cannabis are known as cannabinoids, and THC is considered one of the most important and active cannabinoids. Medical cannabis users can experience a variety of side effects which include mood swings, lack of coordination, increased appetite, red eyes, dry mouth, nausea, coughing, sore throat, and decreased reaction time. Therefore, such side effects may adversely affect the introduction of medical cannabis. Hence, such factors are expected to impede the growth potential of the market during the forecast period.

Drivers, Trends, and Challenges have an impact on market dynamics, which can impact businesses. Find more insights in a sample report!

What are the key data covered in this medical marijuana market report?

Gain instant access to 17,000+ market research reports.

Technavio's SUBSCRIPTION platform

Related Reports:

The marijuana market is estimated to grow at a CAGR of 24.86% between 2022 and 2027. The size of the market is forecasted to increase by USD 48,197.88 million. Furthermore, this report extensively covers market segmentation by product (medical marijuana and recreational marijuana), type (oil, tinctures, and flower), and geography (North America, Europe, APAC, South America, and the Middle East and Africa). The increasing legalization of marijuana is notably driving the marijuana market growth.

The US cannabis market is projected to increase by USD 46,904.91 million and the market size is estimated to grow at a CAGR of 24.03% between 2022 and 2027. Furthermore, this report extensively covers market segmentation by derivative type (CBD, THC, and balanced THC and CBD) and product (medical and recreational). The rising millennial population in key cannabis markets is driving the market growth.

Medical Marijuana Market Scope

Report Coverage

Details

Historic period

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 21.86%

Market growth 2023-2027

USD 21,248.51 million

Market structure

Fragmented

YoY growth 2022-2023 (%)

19.59

Regional analysis

North America, APAC, Europe, South America, and Middle East and Africa

Performing market contribution

North America at 47%

Key countries

US, Canada, Germany, UK, and France

Competitive landscape

Leading Companies, Market Positioning of Companies, Competitive Strategies, and Industry Risks

Key companies profiled

Aurora Cannabis Inc., Canopy Growth Corp., Cresco Labs LLC, Cronos Group Inc., CV Sciences Inc., Etain LLC, HEXO Corp., Isodiol International Inc., Jazz Pharmaceuticals Plc, Khiron Life Sciences Corp, Maricann Group Inc, Medical Marijuana Inc., MediPharm Labs Inc., Organigram Holdings Inc., Phoena Holdings Inc, Skye Bioscience Inc., Tikun Olam, Tilray Brands Inc., Trevena Inc, and Verano Holdings LLC

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of Contents

1 Executive Summary

2 Market Landscape

3 Market Sizing

4 Historic Market Size

5 Five Forces Analysis

6 Market Segmentation by Type

7 Market Segmentation by Product

8 Customer Landscape

9 Geographic Landscape

10 Drivers, Challenges, and Trends

11 Company Landscape

12 Company Analysis

13 Appendix

About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com

SOURCE Technavio


These press releases may also interest you

at 08:30
Knight Therapeutics Inc., ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo Biotoscana de Especialidad S.A. de C.V. has obtained regulatory approval by COFEPRIS, the Mexican health...

at 08:30
Sienna Senior Living Inc. ("Sienna" or the "Company") today announced a dividend of $0.078 per common share of the Company (each, a "Common Share") for the month of October 2024, representing $0.936 per Common Share on an annualized basis. The...

at 08:27
Elanco Animal Health today unleashed the first ever real-world data demonstrating the efficacy and impact of its Canine Parvovirus Monoclonal Antibody (CPMA), the first and only USDA Conditionally Approved targeted treatment for canine parvovirus....

at 08:25
Ibex Medical Analytics (Ibex), the leader in artificial intelligence (AI)-powered cancer diagnostics, today announced the publication of a clinical study evaluating Ibex Breast HER2 in a peer-reviewed journal, JCO Precision Oncology.1 Showcasing the...

at 08:25
MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract related to the company's second generation of proprietary...

at 08:25
Vir Biotechnology, Inc. today announced it will present new data from the Phase 2 SOLSTICE clinical trial evaluating the efficacy and safety profile of tobevibart, an investigational monoclonal antibody (mAb), and elebsiran, an investigational small...



News published on and distributed by: